Indian Medicine Online Shopping Guide - Direct Shipping - Purchasing Agent

September 15, 2025

Why do people buy Indian medicines online?

Price advantage

Indian generic drugs are typically priced significantly lower than original drugs and domestically produced drugs in the Chinese market. India is one of the world's largest producers of generic drugs, and its pharmaceutical industry benefits from economies of scale and lower production costs. For example, some targeted therapies for cancer treatment cost only one-fifth or even less in India than in China. For many patients with limited financial resources, price is a crucial factor in their drug selection. The low prices of Indian generic drugs allow patients to access high-quality treatment at a lower cost.

Drug quality

Indian generic drugs enjoy a high reputation in the international market. Many Indian pharmaceutical companies adhere to stringent production standards and have obtained certifications from internationally authoritative organizations, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). These companies' generic drugs are indistinguishable from the original drugs in terms of efficacy and safety, meeting international standards and ensuring drug quality.

Supply and demand contradiction

China's pharmaceutical market faces drug shortages and supply-demand imbalances, particularly in the treatment of rare and chronic diseases. Some imported drugs are expensive and in short supply, while domestically produced drugs cannot fully meet market demand. Indian generic drugs, with their wide variety and ample supply, fill this gap, providing patients with more treatment options.

Class contradictions

In China, truly powerful figures have the authority to use and be reimbursed for imported drugs , while ordinary people, after filtering information through various channels,

A lack of understanding of imported drugs, traditional Chinese medicine, domestically produced drugs, and generic drugs, coupled with financial constraints, leads to low demand for imported drugs. Instead, people prefer traditional Chinese medicine and its remedies. However , there are countless middle-class people in China who are aware of double-blind testing, clinical trials, and the fact that traditional Chinese medicine cannot be administered via intravenous injection; they simply lack a reliable purchasing channel. We have solved this problem for them.

CARE AND MORE LLC, caresandmore.net is a company registered in Wyoming, USA. It specializes in original and generic drugs, offering online shopping, direct shipping, and purchasing services. It also provides access to Indian anti-cancer drugs, primarily exporting to Asia and the Americas. CARE AND MORE LLC is a trusted health expert.

I'd like to buy cancer drugs from India. Are there any recommended channels?

Sharing information on purchasing Indian anticancer drugs and precautions.

How effective are Indian anti-cancer drugs ? How do they compare to imported drugs in China?

India, known as the "world's pharmacy," boasts world-leading generic drug technology. Professional institutions have proven through ingredient testing that these drugs achieve 99.99% similarity to imported anti-cancer drugs. It's also worth noting that beyond anti-cancer medications, many other Indian medicines, such as simple topical treatments for arthritis, insect bites, and skin conditions, are also remarkably effective.

Why does India have cheap generic cancer drugs while China does not?

First, India has a very high level of generic drug quality.

Second, the Indian government's inaction.

Normally, generic drugs can only be marketed after the patent for the brand-name drug expires; otherwise, the patent would be useless. For example, the global patent for "Gleevec" expired in 2013. Before that, theoretically, other manufacturers could not sell generic versions, otherwise it would be infringement. The United States, Europe, and China all strictly enforce drug patent protection. Many pharmaceutical companies in these countries had long wanted to produce generic versions of "Gleevec," and many companies had even finished manufacturing the generic versions, but they could only keep them in warehouses, afraid to sell them, waiting anxiously for the clock to strike midnight on the day the patent expired in 2013.

But the Indian government was unyielding and ruthless, resorting directly to the most ruthless measure in its patent law: compulsory licensing.

"Compulsory licensing" is a check and balance added to patent law to prevent companies from abusing patent rights. Simply put, under certain circumstances, the government can, without the patent holder's consent and before the patent expires, forcibly authorize generic drug companies to legally manufacture and sell the same drugs by paying a small patent transfer fee. In short, the government can "force a purchase."

The original purpose of the "compulsory licensing" regulation was to prevent developing countries from being unable to guarantee basic medical care and national security for their citizens due to the inability to afford patented drugs. It is usually used during outbreaks of infectious diseases, such as AIDS and Ebola. Many countries have "compulsory licensing" for anti-AIDS drugs, which are sold very cheaply to ensure that everyone can use them. These include not only African countries, but also countries that are not particularly poor, such as Thailand and Brazil.

The controversy surrounding "compulsory licensing" for anti-cancer drugs is much greater because cancer is not contagious and its harm to society as a whole is not as great as that of infectious diseases, so it does not pose a threat to national security. But conversely, if the poor cannot afford anti-cancer drugs and can only wait to die, does that also constitute a lack of basic medical care for citizens, thus harming national security? As a result, various stakeholders have been arguing endlessly.

While other countries were still debating democratic principles, the Indian government acted decisively, without hesitation granting "compulsory licenses" to several of the most important anti-cancer drugs from European and American pharmaceutical companies, authorizing Indian domestic manufacturers to produce generic versions. These included drugs like Gleevec, Iressa, and Sorafenib, mentioned earlier. The Indian government's justification was that these drugs were simply too good for the Indian people to afford, hence the concession. After the generic versions appeared, the prices of these drugs in India instantly dropped by more than 90%. Because Indian generic drug companies are highly skilled, producing high-quality drugs at affordable prices in sufficient quantities, they effectively met domestic demand in India.